Literature DB >> 20029441

Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC.

Jason E Faris1, M Dror Michaelson.   

Abstract

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.

Entities:  

Year:  2010        PMID： 20029441     DOI： 10.1038/nrclinonc.2009.173

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  10 in total

1.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

3.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

Authors:  O Iliopoulos; A P Levy; C Jiang; W G Kaelin; M A Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

4.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Authors:  Martin E Gore; Cezary Szczylik; Camillo Porta; Sergio Bracarda; Georg A Bjarnason; Stéphane Oudard; Subramanian Hariharan; Se-Hoon Lee; John Haanen; Daniel Castellano; Eduard Vrdoljak; Patrick Schöffski; Paul Mainwaring; Alejandra Nieto; Jinyu Yuan; Ronald Bukowski
Journal:  Lancet Oncol       Date:  2009-07-15       Impact factor: 41.316

5.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

6.  Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Authors:  Brian I Rini; Susan Halabi; Jonathan E Rosenberg; Walter M Stadler; Daniel A Vaena; San-San Ou; Laura Archer; James N Atkins; Joel Picus; Piotr Czaykowski; Janice Dutcher; Eric J Small
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

7.  Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

8.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

9.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors:  Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal:  Lancet       Date:  2008-07-22       Impact factor: 79.321

10.  Sunitinib efficacy against advanced renal cell carcinoma.

Authors:  Robert J Motzer; M Dror Michaelson; Jonathan Rosenberg; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; George Wilding
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450
  10 in total
  6 in total

Review 1.  The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility.

Authors:  Bradley C Holland; Zubin Shetty; Shaheen Alanee
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

Review 2.  Systemic therapy in hepatocellular carcinoma.

Authors:  Stephen H Wrzesinski; Tamar H Taddei; Mario Strazzabosco
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

Review 3.  Chronic inflammation and immunologic-based constraints in malignant disease.

Authors:  Devin B Lowe; Walter J Storkus
Journal:  Immunotherapy       Date:  2011-10       Impact factor: 4.196

Review 4.  A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.

Authors:  Z Mihaly; Z Sztupinszki; P Surowiak; B Gyorffy
Journal:  Curr Cancer Drug Targets       Date:  2012-09       Impact factor: 3.428

5.  Silencing of the long non-coding RNA GHET1 inhibits cell proliferation and migration of renal cell carcinoma through epithelial-mesenchymal transition.

Authors:  Wenjie Xie; Xin Liu; Qiang Chen; Ming Ma; Xiaorong Yang; Binbin Gong; Ting Sun; Jie Chen
Journal:  Oncol Lett       Date:  2019-01-25       Impact factor: 2.967

6.  Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis.

Authors:  Yang Liao; Haifeng Hou; Zhenhua Han; Ying Liu
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.